Immunoregulatory drugs

Mechanistic basis for use in organ transplantation

Manikkam Suthanthiran, Terry B. Strom

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Multiple immunoregulatory drugs, capable of constraining cell activation, differentiation, and/or proliferation, and each with distinct side effects, are currently used in the clinic to facilitate organ engraftment. Cyclesporine, azathioprine, corticosteroids, FK506 (tacrolimus), and RS61443 (mycophenolate mofetil) have already been approved by the United States Food and Drug Administration. Rapamycin (sirolimus), mizoribine, and 15-deoxyspergualin are being explored for their clinical efficacy. Based on their subcellular site of action, the immunosuppressants can be considered as: inhibitors of transcription (cyclosporine, tacrolimus), inhibitors of nucleotide synthesis (azathioprine, mycophenolate mofetil, miteribine), inhibitors of growth factor signal transduction (sirolimus), and inhibitors of differentiation (15-deoxyspergualin). Clearly, the transplant clinician now has a greater choice in the selection and application of immunosuppressants in the clinic for the fine regulation of anti-allograft immunity. The existing hypothesis regarding the mechanisms of action of immunosuppressants is that they all function to prevent allograft rejection by preventing/inhibiting cell activation, cytokine production, differentiation, and/or proliferation. A complementary supposition is that some of the immunosuppressants might regulate the anti-allograft repertory by stimulating the expression of immunosuppressive molecules and/or cells.

Original languageEnglish
Pages (from-to)651-657
Number of pages7
JournalPediatric Nephrology
Volume11
Issue number5
DOIs
Publication statusPublished - 1 Oct 1997
Externally publishedYes

Fingerprint

Organ Transplantation
Immunosuppressive Agents
Tacrolimus
Sirolimus
Mycophenolic Acid
Allografts
Pharmaceutical Preparations
Azathioprine
United States Food and Drug Administration
Cyclosporine
Cell Differentiation
Immunity
Signal Transduction
Intercellular Signaling Peptides and Proteins
Adrenal Cortex Hormones
Nucleotides
Cell Proliferation
Cytokines
Transplants
gusperimus

Keywords

  • Anti-allograft response
  • Cytokines
  • Immunosuppressants

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Immunoregulatory drugs : Mechanistic basis for use in organ transplantation. / Suthanthiran, Manikkam; Strom, Terry B.

In: Pediatric Nephrology, Vol. 11, No. 5, 01.10.1997, p. 651-657.

Research output: Contribution to journalReview article

@article{9019066e110844d3a09674346cec564d,
title = "Immunoregulatory drugs: Mechanistic basis for use in organ transplantation",
abstract = "Multiple immunoregulatory drugs, capable of constraining cell activation, differentiation, and/or proliferation, and each with distinct side effects, are currently used in the clinic to facilitate organ engraftment. Cyclesporine, azathioprine, corticosteroids, FK506 (tacrolimus), and RS61443 (mycophenolate mofetil) have already been approved by the United States Food and Drug Administration. Rapamycin (sirolimus), mizoribine, and 15-deoxyspergualin are being explored for their clinical efficacy. Based on their subcellular site of action, the immunosuppressants can be considered as: inhibitors of transcription (cyclosporine, tacrolimus), inhibitors of nucleotide synthesis (azathioprine, mycophenolate mofetil, miteribine), inhibitors of growth factor signal transduction (sirolimus), and inhibitors of differentiation (15-deoxyspergualin). Clearly, the transplant clinician now has a greater choice in the selection and application of immunosuppressants in the clinic for the fine regulation of anti-allograft immunity. The existing hypothesis regarding the mechanisms of action of immunosuppressants is that they all function to prevent allograft rejection by preventing/inhibiting cell activation, cytokine production, differentiation, and/or proliferation. A complementary supposition is that some of the immunosuppressants might regulate the anti-allograft repertory by stimulating the expression of immunosuppressive molecules and/or cells.",
keywords = "Anti-allograft response, Cytokines, Immunosuppressants",
author = "Manikkam Suthanthiran and Strom, {Terry B.}",
year = "1997",
month = "10",
day = "1",
doi = "10.1007/s004670050359",
language = "English",
volume = "11",
pages = "651--657",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Immunoregulatory drugs

T2 - Mechanistic basis for use in organ transplantation

AU - Suthanthiran, Manikkam

AU - Strom, Terry B.

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Multiple immunoregulatory drugs, capable of constraining cell activation, differentiation, and/or proliferation, and each with distinct side effects, are currently used in the clinic to facilitate organ engraftment. Cyclesporine, azathioprine, corticosteroids, FK506 (tacrolimus), and RS61443 (mycophenolate mofetil) have already been approved by the United States Food and Drug Administration. Rapamycin (sirolimus), mizoribine, and 15-deoxyspergualin are being explored for their clinical efficacy. Based on their subcellular site of action, the immunosuppressants can be considered as: inhibitors of transcription (cyclosporine, tacrolimus), inhibitors of nucleotide synthesis (azathioprine, mycophenolate mofetil, miteribine), inhibitors of growth factor signal transduction (sirolimus), and inhibitors of differentiation (15-deoxyspergualin). Clearly, the transplant clinician now has a greater choice in the selection and application of immunosuppressants in the clinic for the fine regulation of anti-allograft immunity. The existing hypothesis regarding the mechanisms of action of immunosuppressants is that they all function to prevent allograft rejection by preventing/inhibiting cell activation, cytokine production, differentiation, and/or proliferation. A complementary supposition is that some of the immunosuppressants might regulate the anti-allograft repertory by stimulating the expression of immunosuppressive molecules and/or cells.

AB - Multiple immunoregulatory drugs, capable of constraining cell activation, differentiation, and/or proliferation, and each with distinct side effects, are currently used in the clinic to facilitate organ engraftment. Cyclesporine, azathioprine, corticosteroids, FK506 (tacrolimus), and RS61443 (mycophenolate mofetil) have already been approved by the United States Food and Drug Administration. Rapamycin (sirolimus), mizoribine, and 15-deoxyspergualin are being explored for their clinical efficacy. Based on their subcellular site of action, the immunosuppressants can be considered as: inhibitors of transcription (cyclosporine, tacrolimus), inhibitors of nucleotide synthesis (azathioprine, mycophenolate mofetil, miteribine), inhibitors of growth factor signal transduction (sirolimus), and inhibitors of differentiation (15-deoxyspergualin). Clearly, the transplant clinician now has a greater choice in the selection and application of immunosuppressants in the clinic for the fine regulation of anti-allograft immunity. The existing hypothesis regarding the mechanisms of action of immunosuppressants is that they all function to prevent allograft rejection by preventing/inhibiting cell activation, cytokine production, differentiation, and/or proliferation. A complementary supposition is that some of the immunosuppressants might regulate the anti-allograft repertory by stimulating the expression of immunosuppressive molecules and/or cells.

KW - Anti-allograft response

KW - Cytokines

KW - Immunosuppressants

UR - http://www.scopus.com/inward/record.url?scp=0030808658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030808658&partnerID=8YFLogxK

U2 - 10.1007/s004670050359

DO - 10.1007/s004670050359

M3 - Review article

VL - 11

SP - 651

EP - 657

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 5

ER -